Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

61 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Neurocrine Biosciences Announces Appointment of Christine A. Poon to Board of Directors
PR
NEUROCRINE BIOSCIENCES INC : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
DARE BIOSCIENCE, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
REGULUS THERAPEUTICS INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
Neurocrine Biosciences : 2021 Annual Report*
PU
NEUROCRINE BIOSCIENCES INC : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
Dare Bioscience : 2021 Proxy Statement
PU
REGULUS THERAPEUTICS INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
FATE THERAPEUTICS INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
Transcript : Fate Therapeutics, Inc. - Shareholder/Analyst Call
NEUROCRINE BIOSCIENCES INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
Neurocrine Biosciences : Announces Appointment of Johanna Mercier to Board of Directors
AQ
Neurocrine Biosciences : Announces Appointment of Johanna Mercier to Board of Directors
PR
Dare Bioscience : Current Report (SEC Filing - 8-K)
PU
Daré Bioscience Reports Second Quarter 2020 Financial Results and Provides Company Update
GL
REGULUS THERAPEUTICS INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
NEUROCRINE BIOSCIENCES INC : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
Fate Therapeutics Announces Changes to its Board of Directors
GL
Neurocrine Biosciences : Announces Appointment of Shalini Sharp to Board of Directors
PR
REGULUS THERAPEUTICS INC. : Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
Regulus Therapeutics Inc. announced that it has received $42.736888 million in funding from a group of investors
CI
Neurocrine Biosciences : Announces Appointment of Leslie V. Norwalk to Board of Directors
PR
Daré Bioscience, Inc. Announces Board Changes
CI
Daré Bioscience Announces Appointment of Dr. William H. Rastetter as Chairman of the Board of Directors
GL
Daré Bioscience Announces Appointment of Dr. William H. Rastetter as Chairman of the Board of Directors
CI
ViaSat : CONNECT to Honor Three Distinguished Innovators at Annual Awards
PU
Transcript : Daré Bioscience, Inc. - Shareholder/Analyst Call
Neurocrine Biosciences : Chief Executive Officer of Neurocrine Biosciences, Kevin Gorman, Ph.D., Named EY Entrepreneur Of The Year® 2018 San Diego
PR
Daré Bioscience, Inc. Announces Board Changes
CI
Cerulean Pharma : Urges Stockholders to Vote for Proposals at July 19, 2017 Special Stockholder Meeting
BU
Cerulean Pharma : and Daré Announce Awards for Daré CEO
BU
Transcript : Illumina Inc., Q4 2015 Earnings Call, Feb 02, 2016
Illumina Inc. Announces Board Changes
CI
Illumina : Forms New Company to Enable Early Cancer Detection via Blood-Based Screening
BU
Grail announced that it has received $100 million in funding from Arch Venture Partners, L.P., Illumina Inc., Sutter Hill Ventures, Bezos Expeditions, LLC, and other investors.
CI
Distinguished Life Sciences Leaders to be Honored at CLSA's 2015 Pantheon DiNA Awards Ceremony
GL
Neurocrine Biosciences : Announces the Appointment of George J. Morrow to its Board of Directors
PR
Biogen : Neurocrine Biosciences Announces the Appointment of Dr. Alfred W. Sandrock to its Board of Directors
PR
Corporate Directors Forum : Honors Six San Diego Executives with 2015 Director of The Year Awards
PR
Transcript : Illumina Inc. - Shareholder/Analyst Call
Capital One Financial : Project Update, Awards, Appointment, Product Launch, and Sponsorship - Research Reports on D.R. Horton, Mallinckrodt, Illumina, Ventas and Capital One Financial
PR
Fate Therapeutics, Inc. Announces Board Changes
CI
Regulus Therapeutics Inc. Elects Bruce L.A. Carter, Mark G. Foletta, William Rastetter and Douglas Williams as Directors
CI
Regulus Therapeutics Inc : Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
PR
Regulus Appoints William H. Rastetter to its Board
CI
Cerulean Pharma Inc. announced that it has received $28 million from a group of investors.
CI
Fate Therapeutics, Inc. Appoints Christian Weyer as President and Chief Executive Officer
CI
Illumina, Inc. : Illumina Announces Preliminary Voting Results for 2012 Annual Meeting of Stockholders
BU
Illumina, Inc. : Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote for the Election of All Illumina Nominees Using Management’s WHITE Proxy Card
PU
Illumina, Inc. : Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote for the Election of All Illumina Nominees Using Management's WHITE Proxy Card
BU
No results for this search
  1. Stock Market
  2. Advanced search
  3. William Rastetter
  4. News